Moderna Stock Price and Forecast: MRNA collapses as US and UK go back to normal life


  • Moderna stock slides again as investors lose faith.
  • MRNA shares also suffering as UK fully opens up and Biden says normal is on the way.
  • Moderna lacks alternative revenue streams.

 FXStreet had turned bearish on this stock after resutls in November, but the emergence of the Omicron variant did change things somewhat. Moderna (MRNA) shares spiked as panic gripped markets and Omicron was an unknown entity.

The shares quickly spiked to nearly $380 from a post-earnings low of $220. However, Moderna put in a bearish shooting star candle that signified impending losses. The news was finally confirmed in our view when on December 20 Moderna said its jab was effective against Omicron. Moderna shares spiked intraday but actually closed 6% lower as investors ditched the name.

The reason as we now apparently know is that it appears Omicron is much less serious that other variants. More transmissable, yes, but the variant results in much fewer hospitalizations. Experts have now come to the conclusion that this is the end game for covid. This will be the final covid winter. This appears to have gotten confirmtaion from the UK yesterday as emabttled Prime Minister Johnson gets to luckily deflect attention away from him by announcing an end to restrictions. In the US President Biden says things are nearly back to normal. Europe is a little further behind, but already some countries such as Ireland are significantly easing restrictions.

Moderna Stock News

Moderna cracked below key support at $188 when it lost nearly 7% yesterday. Markets are not in a charitable mood, and increased attention is now being focused on potential short names and dumping high growth stocks. FXStreet has identified before the one-trick pony that MRNA potentially is. It is hugely reliant on covid vaccines for revenue. It does have some other products in the pipeline as shown below, but none are yet commercial.

Source: Moderna www.modernatx.com/pipeline

Moderna Stock Forecast

$188.40 was a big level going back to February of last year. The stock eventually broke above in summer 2021 and staged a successful pullback test before marching higher. Now that it is broken, the next target is $157.70 and then some decent volume support at $147. Resistance at $211 is the short-term pivot.

Moderna (MRNA) chart, daily

 


Like this article? Help us with some feedback by answering this survey:

Share: Feed news

Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.

If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.

FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.

The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.

Recommended content


Recommended content

Editors’ Picks

EUR/USD clings to modest gains near 1.0750 after mixed US data

EUR/USD clings to modest gains near 1.0750 after mixed US data

EUR/USD clings to marginal daily gains at around 1.0750 in the American session on Tuesday. The US Dollar struggles to gather strength following the mixed macroeconomic data releases, allowing the pair to hold its ground.

EUR/USD News

GBP/USD rebounds above 1.2700 as USD weakens

GBP/USD rebounds above 1.2700 as USD weakens

GBP/USD picks up some pace and trades in the green above 1.2700 after struggling to gain traction in the early European session. The mixed data releases from the US makes it difficult for the USD to stay resilient against its rivals, allowing the pair to edge higher.

GBP/USD News

Gold hovers around $2,330 as demand for the USD recedes

Gold hovers around $2,330 as demand for the USD recedes

After declining toward $2,300, Gold reversed its direction and recovered above $2,320. The benchmark 10-year US Treasury bond yield stays in negative territory below 4.3% after latest US data, helping XAU/USD stretch higher.

Gold News

Is the Bitcoin price bottom here?

Is the Bitcoin price bottom here?

Bitcoin price is currently supported by the 1-day to 1-week UTXO Age Bands. On-chain data suggests that crowd FOMO is calming down, signaling a potential BTC price bottom.

Read more

May Retail Sales miss suggests consumer momentum fading

May Retail Sales miss suggests consumer momentum fading

The downside miss for May retail sales amid downward revisions to past data paint a picture of a softening consumer, but weakness appears overstated when considering lower inflation. 

Read more

Forex MAJORS

Cryptocurrencies

Signatures